Panagora Asset Management Inc. Has $49.70 Million Stake in Humana Inc. (NYSE:HUM)

Panagora Asset Management Inc. trimmed its stake in Humana Inc. (NYSE:HUM) by 53.0% in the third quarter, reports. The firm owned 127,716 shares of the insurance provider’s stock after selling 143,863 shares during the period. Panagora Asset Management Inc.’s holdings in Humana were worth $49,701,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of HUM. Sugarloaf Wealth Management LLC grew its holdings in Humana by 346.7% during the 3rd quarter. Sugarloaf Wealth Management LLC now owns 67 shares of the insurance provider’s stock worth $26,000 after acquiring an additional 52 shares during the period. Canton Hathaway LLC bought a new position in Humana in the 3rd quarter valued at about $52,000. Allworth Financial LP lifted its position in Humana by 411.5% in the 3rd quarter. Allworth Financial LP now owns 133 shares of the insurance provider’s stock valued at $52,000 after acquiring an additional 107 shares in the last quarter. Herold Advisors Inc. bought a new position in shares of Humana during the 3rd quarter worth approximately $54,000. Finally, Moors & Cabot Inc. increased its stake in shares of Humana by 4,267.6% during the 3rd quarter. Moors & Cabot Inc. now owns 62,500 shares of the insurance provider’s stock worth $57,000 after purchasing an additional 61,069 shares during the last quarter. Hedge funds and other institutional investors own 91.96% of the company’s stock.

In other Humana news, CEO Bruce D. Broussard sold 50,006 shares of the stock in a transaction that occurred on Friday, November 5th. The shares were sold at an average price of $454.70, for a total value of $22,737,728.20. The sale was disclosed in a document filed with the SEC, which is available through this link. 0.40% of the stock is owned by company insiders.

Shares of NYSE HUM opened at $391.66 on Friday. Humana Inc. has a one year low of $351.20 and a one year high of $475.44. The firm has a market cap of $50.34 billion, a PE ratio of 18.91, a PEG ratio of 1.24 and a beta of 0.94. The firm has a fifty day moving average of $438.41 and a 200 day moving average of $431.97. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.72 and a current ratio of 1.72.

Humana (NYSE:HUM) last posted its earnings results on Wednesday, November 3rd. The insurance provider reported $4.83 EPS for the quarter, beating the Zacks’ consensus estimate of $4.61 by $0.22. The company had revenue of $20.70 billion for the quarter, compared to analysts’ expectations of $20.91 billion. Humana had a net margin of 3.30% and a return on equity of 14.95%. Humana’s revenue for the quarter was up 3.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted $3.08 earnings per share. On average, equities analysts predict that Humana Inc. will post 20.5 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, January 28th. Investors of record on Friday, December 31st will be issued a $0.70 dividend. The ex-dividend date of this dividend is Thursday, December 30th. This represents a $2.80 annualized dividend and a yield of 0.71%. Humana’s dividend payout ratio (DPR) is 13.52%.

Several research analysts have commented on the stock. Credit Suisse Group raised their price target on shares of Humana from $500.00 to $513.00 and gave the company an “outperform” rating in a report on Thursday, November 4th. Truist Securities boosted their price target on shares of Humana from $500.00 to $520.00 and gave the stock a “hold” rating in a research note on Wednesday, January 5th. UBS Group restated a “hold” rating and issued a $486.00 price objective on shares of Humana in a research report on Friday, January 7th. Royal Bank of Canada boosted their price target on shares of Humana from $479.00 to $525.00 and gave the company an “outperform” rating in a research report on Thursday, November 4th. Finally, Sanford C. Bernstein reduced their price target on shares of Humana from $470.00 to $431.00 in a research report on Tuesday. Eight research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $486.21.

About Humana

Humana Inc engages in the provision of health insurance services. The firm operates through the following segments: Retail, Group and Specialty and Healthcare Services. The Retail segment consists of products sold on a retail basis to individuals including medical and supplemental benefit plans such as Medicare, and State-based Medicaid contracts.

See Also: Understanding and Trading Breakout Stocks

Want to see what other hedge funds are holding HUM? Visit to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM).

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with's FREE daily email newsletter.